The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.04. The company had revenue of $344.50 million for the quarter, compared to the consensus estimate of $349.85 million. During the same quarter last year, the company posted $0.79 earnings per share. West Pharmaceutical Servicess revenue was up 6.1% compared to the same quarter last year. On average, analysts expect West Pharmaceutical Services to post $1.60 EPS for the current fiscal year and $1.85 EPS for the next fiscal year.
Thai pharmaceutical company steps up Burma presence
The Firdapse(TM) currently being used in Catalyst’s Phase 3 pivotal trial is the same product approved for marketing in Europe and has been shown to be more stable than the free base form of 3,4-DAP. This enhanced stability is expected to provide LEMS patients with the assurance that their drug has the correct potency and purity in every dose. — Catalyst has previously reported that another pharmaceutical company is conducting a Phase 2 trial with a different formulation of amifampridine (3,4-DAP) for the treatment of LEMS. While there can be no assurance, Catalyst continues to believe that its development program for the product is further along in the development than this other company. — Catalyst believes that the LEMS patient community deserves the benefits of having an approved product to treat their disease that has met the FDA’s stringent burden of proof in safety and efficacy and is widely available for use by physicians treating LEMS patients.
Catalyst Pharmaceutical Announces Social Media Presence
Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed. The study also provides a comprehensive financial and product review of key players in the biopharmaceutical industry in India.
( CPRX ), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, today announced that it has joined the social media conversation with a company blog and Twitter handle, which can be found at CatalystPharmaBlog.com and @CatalystPharma respectively. “We are embracing social media to engage with and better understand the patient communities we intend to serve,” said Patrick J. McEnany, Chairman and CEO of Catalyst. “We are developing drugs for patients with rare, orphan diseases, and that means we need to go beyond traditional methods of communications to reach and learn from these patients, their families and their care providers.” Catalyst will use these social media channels to foster conversations between Catalyst and the Lambert-Eaton Myasthenic Syndrome (LEMS) patient community and company stakeholders. Information distributed via the corporate blog and Twitter will provide meaningful updates, valuable information and relevant resources for the LEMS patient community and stakeholders.
The goal will be realised through organic growth and mergers and acquisitions, said Mr Dhawan. Were focusing on expanding in developing countries, as there is more potential in these markets for Mega to compete, he said. Sales totalled $195 million last year, with 30% from Burma, the top contributor. Another 24.8% came from Vietnam, 19.5% from Thailand and the rest from 26 other countries, particularly Chile, Peru and Indonesia. Were very optimistic about the potential for growth in Myanmar [Burma], said Mr Dhawan, adding that Mega has been contacted by several multinational companies about distributing their products in Burma. Mr Dhawan estimates the value of Burmas pharmaceutical business via hospital and pharmacy channels is worth $400 million but has the potential to double over the next 5-7 years.
(NYSE:ALU) a company that provides networking and communications technology, products, and services to service providers, enterprises, and governments worldwide is currently down (-0.30%) on 3,074,621 shares traded after TheStreet Quant Ratings rated Alcatel-Lucent as a Sell. Alcatel-Lucent, S.A. (NYSE:ALU) is currently down (-18.66%) from its recent 52-week high, which has prompted Growing Stock Report to add the stock to their NYSE Active Stock Watch List and Investor Poll. To find out what other Investors are saying about Alcatel-Lucent, S.A. (NYSE:ALU) GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.